Cart 0
Cart 0
Show all Products
AtlasPlex
MolBoolean
Primary Antibodies
PrEST Control Antigens
Affibody

Atlas Antibodies in Breast Cancer Research

Breast cancer originates in the breast’s ductal or lobular cells and is the most common cancer in women worldwide (but men can also be affected).

There are multiple subtypes, including:

Invasive Ductal Carcinoma (IDC)
IDC is the most common breast cancer subtype, arising from the milk ducts and characterized by tumor cells invading the surrounding breast stroma.

Invasive Lobular Carcinoma (ILC)
ILC originates in the lobules and is defined by its diffuse, single-file growth pattern, often making it more challenging to detect through imaging.

Triple-Negative Breast Cancer (TNBC)
TNBC lacks expression of ER, PR, and HER2, leading to an aggressive clinical course and making it a key focus for immuno-oncology and targeted therapy research.

HER2-Positive Breast Cancer (HER2+)
HER2+ tumors overexpress the HER2/ERBB2 receptor tyrosine kinase, driving rapid proliferation but also offering strong responsiveness to HER2-targeted therapies.

Luminal (Hormone Receptor-Positive) Subtypes
Luminal tumors express estrogen and/or progesterone receptors, typically exhibit slower growth, and respond well to endocrine therapy, making molecular profiling essential for treatment planning.

 

Breast Cancer Biomarker Panel

Atlas Antibodies offers a variety of highly validated antibodies against key breast cancer biomarkers, enabling detailed IHC, IF, and diagnostic research.

Breast Tumor Subtype / Context Biomarker Biological / Prognostic Role Atlas Antibodies Products
HER2-Positive Breast Cancer HER2 / ERBB2 Receptor tyrosine kinase driving proliferation; strong therapeutic target.

Anti-HER2 (AMAb90627)

Anti-ERBB2 (HPA001383)
Luminal A / B (Hormone-Positive) ER / ESR1 Predicts endocrine therapy response; defines luminal subtype.

Anti-ESR1 (AMAb90867)

Anti-ESR1 (HPA000450)
Luminal Tumors PR / PGR Refines endocrine responsiveness; prognostic in ER+ cancers.

Anti-PGR (AMAb91529)


Anti-PGR (HPA017176)
High-Grade & Aggressive Tumors Ki-67 / MKI67 Proliferation index; critical in grading and prognosis.

Anti-MKI67 (AMAb90870)

Anti-MKI67 (HPA000451)
Triple-Negative Breast Cancer (TNBC) EGFR Often overexpressed in TNBC; potential therapeutic target. Anti-EGFR (HPA018530)
HER2-Low / Borderline Cases GRB7 Co-amplified with HER2; helps refine HER2-associated biology. Anti-GRB7 (HPA020056)
Basal-Like / TNBC CK5 / KRT5 Basal cytokeratin identifying basal-like tumors. Anti-KRT5 (HPA059479)
Basal-Like CK14 / KRT14 Basal marker used in molecular subtyping. Anti-KRT14 (HPA023040)
TNBC / Immunotherapy Profiling PD-L1 / CD274 Immune checkpoint; predicts response to immune checkpoint inhibitors. Anti-CD274 (HPA068883)
Genomic Instability / Aggressive Disease p53 / TP53 Mutation common in TNBC and high-grade tumors; marker of genomic instability.

Anti-TP53 (AMAb90956)

Anti-TP53 (HPA051244)
HER2+ & Luminal (ERBB Signaling) ERBB3 Contributes to therapy resistance through HER2/ERBB3 dimerization. Anti-ERBB3 (HPA045396)
Emerging (TNBC & EMT-rich tumors) Vimentin / VIM EMT marker; associated with metastasis and aggressive behavior.

Anti-VIM (AMAb90516)

Anti-VIM (HPA001762)

 

Breast Cancer: Key Cell Line Models & Their Relevance

  • MCF‑7: A luminal A breast cancer cell line (ER+, PR+). Widely used as a hormone‑responsive model. 
  • T‑47D: Another luminal-like line, strong for studying progesterone receptor biology. Wikipedia
  • SK‑BR-3: HER2‑enriched subtype; good for modeling HER2+ disease. 
  • MDA-MB-231: Triple-negative breast cancer (TNBC) line; metastatic, aggressive, and often used for developing antibody‑drug conjugates or invasion studies.
  • HCC and SUM panel: There are many TNBC cell lines (e.g., Hs578T, BT‑549, MDA‑MB‑436) that capture different transcriptional subtypes of TNBC.
  • KAIMRC1: A newer, naturally immortalized breast cancer line; proteomic profiling shows unique pathway differences compared to MCF-7 and MDA-MB-231.

Why this matters: Using a panel of cell lines that reflect the clinical subtypes of breast cancer (ER+, HER2+, TNBC) gives better translational power. Depending on your research goal (e.g., hormone signaling, drug resistance, invasion), picking the right model is critical.

 

Breast Cancer: Cancer Stem Cell (CSC) Perspective

Breast cancer CSCs, identified by CD44⁺/CD24⁻ and ALDH⁺ markers, play a central role in driving tumor aggressiveness. These CSC populations are crucial because they contribute to therapy resistance, metastasis, and tumor relapse.Targeting CSC-associated proteins can be powerful for designing therapies that minimize recurrence.

 

Understanding the molecular characteristics of breast cancer, as indicated by these pathology markers, is essential for personalized treatment decisions. These markers not only assist in diagnosing and classifying breast cancer but also guide therapeutic strategies, contributing to more effective and tailored approaches for patients.

Download the white paper:

Atlas Antibodies in Breast Cancer Research